A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

Allergic Rhinoconjunctivitis Clinical Trial

— AIRS  

Official title:

National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01535118
• Other study ID #: 7243-021
• Status: Completed
• Phase: N/A
• First received: February 14, 2012
• Last updated: February 25, 2015
• Start date: January 2012
• Est. completion date: May 2012

Study information

• Verified date: February 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2765
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies

• 5 years of age or older

• Have a telephone

Exclusion Criteria:

• If less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective

Related Conditions & MeSH terms

• Allergic Rhinoconjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Blaiss MS, Dykewicz MS, Skoner DP, Smith N, Leatherman B, Craig TJ, Bielory L, Walstein N, Allen-Ramey F. Diagnosis and treatment of nasal and ocular allergies: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immun — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)	Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.	Within 12 months prior to survey	No
Primary	Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months	Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated.	Within 12 months prior to survey	No
Primary	Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months	Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated.	Within 12 months prior to survey	No
Primary	Percentage of Participants Who Received Immunotherapy to Treat ARC	Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated.	Within 12 months prior to survey	No
Primary	Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication	Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated.	Within 12 months prior to survey	No
Secondary	Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma	Participants were asked about co-morbid health conditions. The percentage of participants who had received allergy shots to treat ARC and had asthma was calculated.	Within 12 months prior to survey	Yes